Objective To evaluate the effect of high load application of atorvastatin on the clinical outcome of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).Methods Eighty patients diagnosed with AMI were continuously enrolled in this study and randomly divided into two groups:high dose group(n=40) and control group(n=40).Application of high load atorvastatin before operation in loading group.The levels of serum lipid and cardiac function were measured and analyzed.Results The levels of BNP((204±60.3) pg/mL vs.(328.3±67.5) pg/mL;t=1.938,P=0.0315) on 7 days after PCI and levels of LVEF((50.3±6.0)％ vs.(56.9±7.3)％;t=2.169,P=0.019) on 1 month after PCI in high dose group were significantly better than those in control group.Correlation analysis showed that the administration of statin was negatively associated with levels of BNP(r=-0.157,P=0.021) on 7 days after PCI and positively associated with LVEF(r=-0.328,P=0.026) on 1 month after PCI.Conclusion The treatment of high dose statin before PCI may reduce the ischemia-reperfusion injury and prevent the no-reflow development,which therefore improve the cardiac function of AMI patients.

Objective:To evaluate the efficacy of Tongmai-Huaban Decoction combined with conventional western medicine in the treatment of patients with coronary heart disease, and to explore the effects on unstable plaque formation and oxidative stress response. Methods:A total of 120 patients with coronary heart disease in Jiangsu Traditional Chinese Medicine Hospital from March 2020 to March 2021 were randomly divided into two groups by random number table method, with 60 in each group.The control group was treated with aspirin and atorvastatin, and the treatment group was treated with Tongmai-huaban Decoction on the basis of the control group. Both groups were treated for 3 months. The Carotid plaque area and carotid intima-media thickness (cIMT) were measured by color Doppler, the serum MDA and SOD were detected by electrochemiluminescence, the lipid peroxidation (LPO) was detected by double antibody sandwich method, the TNF-α and IL-6 levels were measured by ELISA, and the level of CRP was measured by immunoturbidimetry. The adverse reactions of the two groups were observed, and the clinical efficacy was evaluated. Results:The total effective rate was 91.7% (55/60) in the treatment group and 76.7% (46/60) in the control group, and the difference between the two groups was statistically significant ( χ2=5.016, P=0.024). After treatment, the carotid plaque area [(0.51 ± 0.13) cm 2vs. (0.65 ± 0.16) cm 2, t=5.416] and cIMT [(1.89 ± 0.41) mm vs. (2.11 ± 0.52) mm, t=2.650] in the treatment group were significantly less than those in the control group ( P<0.05); LPO [(3.31 ± 0.83) μmol/L vs. (4.18 ± 1.04) μmol/L, t=5.215], MDA [(2.94 ± 0.77) μmol/L vs. (3.79 ± 0.95) μmol/L, t=5.543] levels were significantly lower than those in the control group ( P<0.05); the level of SOD [(86.56 ± 22.73) U/L vs. (78.79 ± 19.07) U/L, t=2.085] was significantly higher than that of the control group ( P<0.05); the levels of TNF-α, CRP and IL-6 in the treatment group were significantly lower than those in the control group ( t values were 2.557, 6.781 and 6.014, respectively, P<0.05 or P<0.01). The incidence of adverse reactions was 8.3% (5/60) in the treatment group and 10.0% (6/60) in the control group, where there was no significant difference between the two groups ( χ2=0.100, P=0.751). Conclusion:Tongmai-Huaban Decoction combined with conventional western medicine can improve the clinical symptoms of patients with coronary heart disease and reduce plaque instability, inflammatory cytokine level and oxidative stress response.